Posted On: 12/19/2015 4:50:55 PM
Post# of 5066
Let's look at drugs mentioned in HemaXellerate IND application AND approvals PRs
Neupogen- over 1billion annual rev.
http://www.drugs.com/stats/neupogen
Neulasta- over 4 billion! By 2014 (patent expired in 2015 but may have a biosimilar)
http://www.drugs.com/stats/neulasta
Leukine- around 80 - 100 million
https://www.evaluategroup.com/View/349--1002-...ct/leukine
Revolade - could not immediately find rev data but it is a first in class and sold in over 100 countries. It is under the name eltrombopag as well and I'm sure has over 50 million annually. And HemaXellerate will outperform (clinically) all of these.
So do that math! Longs have a great investment and still plenty of time to consider building a position.
Neupogen- over 1billion annual rev.
http://www.drugs.com/stats/neupogen
Neulasta- over 4 billion! By 2014 (patent expired in 2015 but may have a biosimilar)
http://www.drugs.com/stats/neulasta
Leukine- around 80 - 100 million
https://www.evaluategroup.com/View/349--1002-...ct/leukine
Revolade - could not immediately find rev data but it is a first in class and sold in over 100 countries. It is under the name eltrombopag as well and I'm sure has over 50 million annually. And HemaXellerate will outperform (clinically) all of these.
So do that math! Longs have a great investment and still plenty of time to consider building a position.
(0)
(0)
